Research conducted by the Menzies School of Health Research has uncovered significant health risks associated with a unique strain of chronic hepatitis B, particularly affecting First Nations people in Australia. The study focused on the C4 hepatitis B sub-genotype and its severe impact on liver health among Aboriginal and Torres Strait Islander communities.
In the analysis of over 780 individuals across the Northern Territory, researchers discovered alarming rates of liver damage. According to Jane Davies, the study lead and head of the Menzies Hepatitis B program, “22 percent of people in this cohort had significant liver damage, and 16 percent of those had cirrhosis.” Cirrhosis is characterized by severe scarring of the liver, which can lead to critical organ dysfunction.
Professor Davies emphasized the aggressive nature of the C4 sub-genotype, stating, “When we looked at it in the lab at the very detailed genetics of it, it looked like it was very aggressive with respect to these two things”—liver damage and liver cancer. The study confirmed laboratory findings by examining clinical data, revealing a troubling trend in liver health among affected individuals.
Current Treatment and Expanded Guidelines
Under existing Australian treatment guidelines, only 25 percent of those in the studied cohort are receiving appropriate care. The researchers explored the potential benefits of implementing World Health Organization (WHO) expanded treatment guidelines for individuals living with the C4 hepatitis B strain. Professor Davies indicated that under these expanded guidelines, approximately half of those currently untreated would qualify for intervention.
While acknowledging the complexities in broadening treatment access, Professor Davies firmly believes that enhancing support for liver health is critical. “My personal opinion is that we should be treating as many people as we can where there is evidence that we can reduce their risk of progression to liver failure and liver cancer,” she stated.
The discussion around expanding treatment eligibility is nuanced, balancing various factors, including the specific characteristics of the C4 strain and its prevalence within the community. “That’s definitely a nuanced conversation with pros and cons,” Professor Davies added.
Ongoing Efforts to Eliminate Hepatitis B
The findings are part of the broader Hep B PAST program, which aims to eliminate hepatitis B in the Northern Territory. Published in BMC Infectious Diseases, this study represents a significant step towards understanding and addressing the unique challenges faced by First Nations communities regarding hepatitis B.
As public health officials consider the implications of these findings, the urgency to implement effective treatment strategies becomes increasingly apparent. The research not only highlights the risks associated with the C4 hepatitis B strain but also calls for a re-evaluation of current treatment protocols to better serve vulnerable populations.
Through continued investigation and advocacy, researchers like Professor Davies are working towards improved health outcomes for Aboriginal and Torres Strait Islander peoples, aiming to mitigate the long-term consequences of chronic hepatitis B.
